TSXV:GENE

Stock Analysis Report

Executive Summary

Invictus MD Strategies Corp. and its subsidiaries primarily engage in the investment, acquisition, and development of synergistic businesses in the medical cannabis industry in Canada.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Risks

  • Invictus MD Strategies has significant price volatility in the past 3 months.
  • Invictus MD Strategies is not covered by any analysts.

Share Price & News

How has Invictus MD Strategies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.0%

GENE

-5.9%

CA Pharmaceuticals

1.3%

CA Market


1 Year Return

-88.8%

GENE

-46.7%

CA Pharmaceuticals

-0.1%

CA Market

GENE underperformed the Pharmaceuticals industry which returned -46.2% over the past year.

GENE underperformed the Market in Canada which returned -0.4% over the past year.


Share holder returns

GENEIndustryMarket
7 Day-6.0%-5.9%1.3%
30 Day-34.7%-3.4%4.2%
90 Day-42.7%-24.8%1.6%
1 Year-88.8%-88.8%-46.7%-46.7%3.4%-0.1%
3 Year-21.7%-21.7%219.2%217.3%19.1%8.4%
5 Yearn/a286.4%286.4%23.2%5.7%

Price Volatility Vs. Market

How volatile is Invictus MD Strategies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Invictus MD Strategies undervalued based on future cash flows and its price relative to the stock market?

0.26x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Invictus MD Strategies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Invictus MD Strategies to establish if it is available at substantial discount.


Price Based on Earnings

Invictus MD Strategies is loss making, we can't compare its value to the CA Pharmaceuticals industry average.

Invictus MD Strategies is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Invictus MD Strategies, we can't assess if its growth is good value.


Price Based on Value of Assets

Invictus MD Strategies is good value based on assets compared to the CA Pharmaceuticals industry average.


Next Steps

Future Growth

How is Invictus MD Strategies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

97.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invictus MD Strategies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Invictus MD Strategies performed over the past 5 years?

-69.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Invictus MD Strategies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Invictus MD Strategies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Invictus MD Strategies's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Invictus MD Strategies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Invictus MD Strategies has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Invictus MD Strategies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Invictus MD Strategies's financial position?


Financial Position Analysis

Invictus MD Strategies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Invictus MD Strategies's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Invictus MD Strategies's level of debt (13.3%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Invictus MD Strategies's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Invictus MD Strategies has less than a year of cash runway based on current free cash flow.

Invictus MD Strategies has less than a year of cash runway if free cash flow continues to grow at historical rates of 95% each year.


Next Steps

Dividend

What is Invictus MD Strategies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Invictus MD Strategies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Invictus MD Strategies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Invictus MD Strategies has not reported any payouts.

Unable to verify if Invictus MD Strategies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Invictus MD Strategies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Invictus MD Strategies's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Trevor Dixon 0

0.3yrs

Tenure

CA$240,000

Compensation

Mr. Trevor Dixon has been Chief Executive Officer and President of Invictus MD Strategies Corp since May 31, 2019. Mr. Dixon has been Director of Invictus MD Strategies Corp since May 9, 2019 and also serv ...


CEO Compensation Analysis

Trevor's remuneration is higher than average for companies of similar size in Canada.

Trevor's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.0yrs

Average Tenure

The average tenure for the Invictus MD Strategies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.7yrs

Average Tenure

55yo

Average Age

The average tenure for the Invictus MD Strategies board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Invictus MD Strategies individual insiders in the past 3 months.


Recent Insider Transactions

BuyCA$11,04019 Aug 19
Colin Kinsley
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceCA$0.37
BuyCA$500,00009 Jul 19
Trevor Dixon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares1,250,000
Max PriceCA$0.40
SellCA$12,20023 Jan 19
Aaron Bowden
EntityIndividual
Role
Senior Key Executive
Shares10,000
Max PriceCA$1.22
BuyCA$32,13018 Nov 18
Brenda Dixon
EntityIndividual
Role
Chief Scientific Officer
Chief Science Officer
Shares25,500
Max PriceCA$1.26
BuyCA$8,88031 Oct 18
Brenda Dixon
EntityIndividual
Role
Chief Scientific Officer
Chief Science Officer
Shares7,400
Max PriceCA$1.20
BuyCA$76,73630 Oct 18
Brenda Dixon
EntityIndividual
Role
Chief Scientific Officer
Chief Science Officer
Shares57,000
Max PriceCA$1.38
BuyCA$88,92624 Oct 18
Brenda Dixon
EntityIndividual
Role
Chief Scientific Officer
Chief Science Officer
Shares71,000
Max PriceCA$1.28
SellCA$247,12229 Sep 18
Brenda Dixon
EntityIndividual
Role
Chief Scientific Officer
Chief Science Officer
Shares110,000
Max PriceCA$2.26

Ownership Breakdown


Management Team

  • Gene Simmons (69yo)

    Chief Evangelist Officer

    • Tenure: 1.5yrs
  • Larry Heinzlmeir

    Vice President of Marketing & Communications

    • Tenure: 2.7yrs
  • Dan Kriznic (40yo)

    Founder and Advisor to Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: CA$1.09m
  • Aaron Bowden

    • Tenure: 0.3yrs
    • Compensation: CA$30.00k
  • Trevor Dixon

    CEO, President & Director

    • Tenure: 0.3yrs
    • Compensation: CA$240.00k
  • Brenda Dixon

    Chief Science Officer

    • Tenure: 2.4yrs
  • Kathy Love

    Corporate Secretary

    • Tenure: 0yrs
  • Harbir Toor

    Chief Financial Officer

    • Tenure: 0.5yrs
  • Marc Ripa

    Chief Operating Officer

    • Tenure: 0.3yrs

Board Members

  • Keith Stein (55yo)

    Director

    • Tenure: 0.7yrs
  • Paul Sparkes (55yo)

    Chairman

    • Tenure: 0.8yrs
    • Compensation: CA$22.50k
  • Rick Lee (63yo)

    Independent Director

    • Tenure: 0.3yrs
  • Milun Tesovic

    Member of Advisory Board

    • Tenure: 4.4yrs
  • Dario Meli (44yo)

    Member of Advisory Board

    • Tenure: 4.5yrs
  • Colin Kinsley

    Independent Director

    • Tenure: 0.3yrs
  • Trevor Dixon

    CEO, President & Director

    • Tenure: 0.3yrs
    • Compensation: CA$240.00k

Company Information

Invictus MD Strategies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Invictus MD Strategies Corp.
  • Ticker: GENE
  • Exchange: TSXV
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$29.277m
  • Shares outstanding: 124.58m
  • Website: https://www.invictus-md.com

Location

  • Invictus MD Strategies Corp.
  • 15047 Marine Drive
  • Suite 300
  • White Rock
  • British Columbia
  • V4B 1C5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8IS2DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2015
IVIT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2015
GENETSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2015

Biography

Invictus MD Strategies Corp. and its subsidiaries primarily engage in the investment, acquisition, and development of synergistic businesses in the medical cannabis industry in Canada. It produces and sell ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 01:00
End of Day Share Price2019/09/20 00:00
Earnings2019/04/30
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.